Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Allergy Clin Immunol ; 131(4): 1117-29, 1129.e1-5, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22795370

RESUMEN

BACKGROUND: IL-17 is an important cytokine signature of the TH differentiation pathway TH17. This T-cell subset is crucial in mediating autoimmune disease or antimicrobial immunity in animal models, but its presence and role in human disease remain to be completely characterized. OBJECTIVE: We set out to determine the frequency of TH17 cells in patients with cystic fibrosis (CF), a disease in which there is recurrent infection with known pathogens. METHODS: Explanted lungs from patients undergoing transplantation or organ donors (CF samples=18; non-CF, nonbronchiectatic samples=10) were collected. Hilar nodes and parenchymal lung tissue were processed and examined for TH17 signature by using immunofluorescence and quantitative real-time PCR. T cells were isolated and stimulated with antigens from Pseudomonas aeruginosa and Aspergillus species. Cytokine profiles and staining with flow cytometry were used to assess the reactivity of these cells to antigen stimulation. RESULTS: We found a strong IL-17 phenotype in patients with CF compared with that seen in control subjects without CF. Within this tissue, we found pathogenic antigen-responsive CD4+IL-17+ cells. There were double-positive IL-17+IL-22+ cells [TH17(22)], and the IL-22+ population had a higher proportion of memory characteristics. Antigen-specific TH17 responses were stronger in the draining lymph nodes compared with those seen in matched parenchymal lungs. CONCLUSION: Inducible proliferation of TH17(22) with memory cell characteristics is seen in the lungs of patients with CF. The function of these individual subpopulations will require further study regarding their development. T cells are likely not the exclusive producers of IL-17 and IL-22, and this will require further characterization.


Asunto(s)
Fibrosis Quística/patología , Interleucina-17/inmunología , Interleucinas/inmunología , Pulmón/patología , Ganglios Linfáticos/patología , Células Th17/patología , Adulto , Anciano , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/farmacología , Antígenos Fúngicos/inmunología , Antígenos Fúngicos/farmacología , Aspergillus/química , Estudios de Casos y Controles , Proliferación Celular/efectos de los fármacos , Fibrosis Quística/genética , Fibrosis Quística/inmunología , Femenino , Expresión Génica , Humanos , Memoria Inmunológica , Inmunofenotipificación , Interleucina-17/genética , Interleucinas/genética , Pulmón/efectos de los fármacos , Pulmón/inmunología , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/inmunología , Activación de Linfocitos/efectos de los fármacos , Masculino , Persona de Mediana Edad , Pseudomonas aeruginosa/química , Células Th17/efectos de los fármacos , Células Th17/inmunología , Interleucina-22
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA